Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Release Date: July 31, 2025

Expiration Date: July 31, 2026

Activity Overview

Review of data presented at recent conferences on newer therapies for neovascular age-related macular degeneration and diabetic macular edema.

This online activity is designed to update clinicians on data presented at meetings of retina specialists; these include the Retina World Congress that was held from May 8 to 11, 2025, in Fort Lauderdale, Florida; the Association for Research in Vision and Ophthalmology 2025 Annual Meeting that was held from May 4 to 8, 2025, in Salt Lake City, Utah; and the MacularArt 2025 International Conference from June 29 through July 1, 2025, in Paris, France. Expert thought leaders provide insights to help clinicians apply findings to their management of patients with neurovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) when using newer therapies that support longer treatment intervals.

Target Audience

This activity is directed toward retina specialists, comprehensive ophthalmologists, optometrists, and other eye care professionals involved in the treatment of neovascular retinal disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize emerging evidence regarding the management of nAMD
• Summarize emerging evidence regarding the management of DME
• Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of retinal vein occlusion based on clinical presentation and goals of treatment

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.